ClinicalTrials.gg
TerminatedNCT05403541Updated Sep 14, 2026

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

A Phase 3 interventional study of Batoclimab 680 mg SC weekly and Batoclimab 340 mg SC weekly in Generalized Myasthenia Gravis, sponsored by Immunovant Sciences GmbH. Terminated at 93 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Immunovant Sciences GmbH · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
5th of 108
233 · median 56
Started
2022
with 9 others
Phase 3
45 of 144
9 open now
Registered
75th of 144
by date
Lead sponsor
3 of 144
Immunovant Sciences GmbH

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 5th largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2022, is one of 45 in phase 3, and was the 75th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3). Participants who complete Period 3 are eligible to participate in Period 4 (Optional Long-Term extension) according to their treatment assignment in Period 3.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • monoclonal antibody
  • batoclimab
  • IMVT-1401
  • Myasthenia Gravis
  • acetylcholine receptor
  • RVT-1401
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are ≥ 18 years of age at the Screening Visit.
  2. Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification Class II, III, or IVa at the Screening Visit.
  3. Have a QMG score ≥ 11 at the Screening and Baseline Visits.
  4. Have a MG-ADL score of ≥ 5 at the Screening and Baseline Visits.
  5. Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have experienced myasthenic crisis within 3 months of the Screening Visit.
  2. Have had a thymectomy performed \< 6 months prior to the Screening Visit or have a planned thymectomy during the study period.
  3. Have any active or untreated malignant thymoma.
  4. Have received any agent or therapy (exclusive of those identified within inclusion criteria) with properties (e.g., stem cell therapy, chemotherapies) within the past year.
  5. Have used anti-FcRn treatment within 3 months prior to the Screening Visit or have a documented history of non-response to prior anti-FcRn treatment.
  6. Additional exclusion criteria are defined in the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Batoclimab Induction Dose 1 (Period 1)

    Drug: Batoclimab 680 mg SC weekly

  • Experimental
    Batoclimab Induction Dose 2 (Period 1)

    Drug: Batoclimab 340 mg SC weekly

  • Placebo comparator
    Placebo Induction Dose (Period 1)

    Drug: Matching Placebo SC

  • Experimental
    Batoclimab Maintenance Dose 1 (Period 2)

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Batoclimab Maintenance Dose 2 (Period 2)

    Drug: Batoclimab 340 mg SC bi-weekly

  • Placebo comparator
    Placebo Maintenance Dose (Period 2)

    Drug: Matching Placebo SC

Interventions

  • Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

    Also known as: IMVT-1401

  • Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

    Also known as: IMVT-1401

  • DrugMatching Placebo SC

    Placebo

  • Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

    Also known as: IMVT-1401

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab seropositive (AChRAb+) participants

    MG-ADL is an 8-item, participant-reported questionnaire that assesses gMG symptoms and their effects on activities of daily living. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. Total score ranges from 0 to 24, with higher scores indicating greater functional impairment and disability.

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Change from Baseline in Quantitative Myasthenia Gravis (QMG) score in AChRAb+ participants

    QMG is clinician-reported assessment to evaluate muscle weakness in participants with MG. The QMG consists of 13 items ranging from 0 to 3 with 3 being the most severe. Total score ranges from 0 to 39, with higher scores representing greater impairment.

    Time frame: Baseline (Day 1) to Week 12

  2. Change from Baseline in MG-ADL score for AChRAb+ randomized withdrawal participants

    Time frame: Baseline (Week 12) to Week 24

  3. Percentage of AChRAb+ participants with greater than equal to (>=) 3-point improvement in QMG score

    Time frame: Up to Week 12

  4. Percentage of AChRAb+ participants achieving MG-ADL score of 0 or 1 by Week 12

    Time frame: Up to Week 12

  5. Change from Baseline in MG-ADL score in AChRAb- (AChRAb negative) participants

    Time frame: Baseline (Day 1) to Week 12

07

Study locations

93 sites
  • Site Number -1022
    Phoenix, Arizona 85028, United States
  • Site Number -1029
    Scottsdale, Arizona 85251, United States
  • Site Number -1002
    Carlsbad, California 92011, United States
  • Site Number -1009
    Irvine, California 92697, United States
  • Site Number - 1012
    Olive View, California 91342, United States
  • Site Number -1032
    San Francisco, California 94143, United States
  • Site Number - 1027
    Aurora, Colorado 80045, United States
  • Site Number - 1025
    New Haven, Connecticut 06519, United States
  • Site Number -1007
    Clearwater, Florida 33761, United States
  • Site Number -1010
    Maitland, Florida 32751, United States
  • Site Number - 1020
    Miami, Florida 33136, United States
  • Site Number - 1019
    Orlando, Florida 32806, United States
  • Site Number - 1028
    Port Charlotte, Florida 33952, United States
  • Site Number - 1015
    Tampa, Florida 33612, United States
  • Site Number -1011
    Fairway, Kansas 66205, United States
  • Site Number -1003
    Lexington, Kentucky 40536, United States
  • Site Number -1013
    East Lansing, Michigan 48824, United States
  • Site Number - 1024
    Minneapolis, Minnesota 55414, United States
  • Site Number - 1021
    Buffalo, New York 14203, United States
  • Site Number - 1018
    Chapel Hill, North Carolina 27599, United States
  • Site Number - 1008
    Durham, North Carolina 27710, United States
  • Site Number -1004
    Cleveland, Ohio 44195, United States
  • Site Number -1006
    Portland, Oregon 97239, United States
  • Site Number - 1023
    Philadelphia, Pennsylvania 19104, United States
  • Site Number - 1026
    Memphis, Tennessee 38120, United States
  • Site Number -1001
    Austin, Texas 78759, United States
  • Site Number -1016
    Dallas, Texas 75206, United States
  • Site Number - 1034
    Houston, Texas 77030, United States
  • Site Number - 1014
    Round Rock, Texas 78681, United States
  • Site Number -1005
    Charlottesville, Virginia 22908, United States
  • Site Number - 5002
    Buenos Aires, 4190, Argentina
  • Site Number - 5001
    Buenos Aires, C1428AQK, Argentina
  • Site Number - 5003
    Rosario, S2000, Argentina
  • Site Number - 5501
    Ribeirão Preto, 14051-140, Brazil
  • Site Number- 5503
    Rio de Janeiro, 22640-100, Brazil
  • Site Number - 2003
    Vancouver, British Columbia V5Z 1M9, Canada
  • Site Number - 2002
    Toronto, Ontario M5G 2C4, Canada
  • Site Number - 2004
    Montreal, Quebec H3A 2B4, Canada
  • Site Number -8002
    Tbilisi, 00114, Georgia
  • Site Number -8004
    Tbilisi, 00114, Georgia
  • Site Number -8001
    Tbilisi, 00160, Georgia
  • Site Number -8003
    Tbilisi, 00186, Georgia
  • Site Number - 8005
    Tbilisi, 0179, Georgia
  • Site Number - 6507
    Berlin, 10117, Germany
  • Site Number - 6505
    Gummersbach, 51643, Germany
  • Site Number - 6503
    Jena, 7747, Germany
  • Site Number -6504
    Leipzig, 04103, Germany
  • Site Number -6502
    Würzburg, 97074, Germany
  • Site Number -7553
    Budapest, 1082, Hungary
  • Site Number - 7552
    Kistarcsa, 2143, Hungary
  • Site Number - 6004
    Bergamo, 24127, Italy
  • Site Number -6006
    Brescia, 25123, Italy
  • Site Number - 6002
    Genova, 16132, Italy
  • Site Number - 6003
    Milan, 20133, Italy
  • Site Number - 6007
    Naples, 80131, Italy
  • Site Number -6001
    Naples, 80131, Italy
  • Site Number - 4020
    Asahikawa-shi, 078-8510, Japan
  • Site Number - 4014
    Fuchu-shi, 183-0042, Japan
  • Site Number - 4002
    Hanamaki-shi, 025-0082, Japan
  • Site Number - 4013
    Higashimatsushima, 355-0005, Japan
  • Site Number - 4009
    Kawasaki-shi, 216-8511, Japan
  • Site Number - 4012
    Koriyama-shi, 963-8563, Japan
  • Site Number - 4007
    Koshigaya-shi, 343-8555, Japan
  • Site Number - 4011
    Matsuyama, 791-8026, Japan
  • Site Number - 4008
    Miyagi, 983-8520, Japan
  • Site Number - 4003
    Narita-shi, 286-8520, Japan
  • Site Number - 4010
    Osaka, 534-0021, Japan
  • Site Number - 4001
    Osaka, 589-8511, Japan
  • Site Number - 4005
    Tokyo, 160-0023, Japan
  • Site Number - 4016
    Yokohama, 222-0036, Japan
  • Site Number - 4019
    Yokohama, 230-8765, Japan
  • Site Number - 4015
    Yokohama, 236-0004, Japan
  • Site Number - 2601
    Mexico City, 06700, Mexico
  • Site Number - 3007
    Gdansk, 80-214, Poland
  • Site Number -3001
    Katowice, 40-123, Poland
  • Site Number -3004
    Krakow, 31-324, Poland
  • Site Number - 3003
    Krakow, 31-503, Poland
  • Site Number -3002
    Krakow, 31-505, Poland
  • Site Number - 3008
    Lublin, 20-701, Poland
  • Site Number -3006
    Poznan, 61-731, Poland
  • Site Number - 3005
    Warsaw, 01-684, Poland
  • Site Number -7502
    Constanța, 900628, Romania
  • Site Number -7501
    Târgu Mureş, 540136, Romania
  • Site Number -7503
    Timișoara, 300723, Romania
  • Site Number - 9001
    Belgrade, 11000, Serbia
  • Site Number - 9002
    Niš, 1800, Serbia
  • Site Number - 4505
    Daegu, 41944, South Korea
  • Site Number - 4501
    Seoul, 06351, South Korea
  • Site Number -3502
    Barcelona, 08195, Spain
  • Site Number -3505
    Barcelona, 8041, Spain
  • Site Number -3501
    Madrid, 028034, Spain
  • Site Number - 3503
    Madrid, 28046, Spain
  • Site Number - 7002
    Sheffield, S102JF, United Kingdom
08

References and documents

Publications

  • Benatar M, Wiendl H, Nowak R, Zheng Y, Macias W. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol Open. 2024 Jan 10;6(1):e000536. doi: 10.1136/bmjno-2023-000536. eCollection 2024. PubMed 38268752 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jan 2025, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 3, 2022
StartActual
Jun 27, 2022
Primary completionActual
Jan 10, 2025
CompletionActual
Aug 7, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05403541
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Jun 27, 2022
Primary completion
Jan 10, 2025
Completion
Aug 7, 2026
Last update
Sep 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion